Abstract | PURPOSE: METHDS: This retrospective observational study used de-identified data of patients with advanced breast cancer treated with palbociclib, using a nationwide claims database (April 2008 to June 2021). Measures included the type of subsequent therapies after palbociclib (endocrine-based therapy: ET alone, ET + CDK4/6i, and ET + mammalian target of rapamycin inhibitor [mTORi]; chemotherapy; chemotherapy + ET; and others) and their TTFs. The median TTF and 95% confidence interval (CI) were estimated using the Kaplan-Meier method. RESULTS: Of 1170 patients treated with palbociclib, 224 and 235 received subsequent therapies after first- and second-line palbociclib treatment, respectively. Among them, 60.7% and 52.8% were treated with endocrine-based therapies as first subsequent therapy, including ET + CDK4/6i (31.2% and 29.8%, respectively). The median TTF (95% CI) of ET alone, ET + CDK4/6i, and ET + mTORi as first subsequent therapy after first-line palbociclib were 4.4 (2.8-13.7), 10.9 (6.5-15.6), and 6.1 (5.1-7.2) months, respectively. No apparent relationship between the treatment duration of prior ET + palbociclib and subsequent abemaciclib was observed. CONCLUSION: This real-world study revealed that one-third of the patients received sequential CDK4/6i after ET + palbociclib, and treatment duration of ET + CDK4/6i following ET + palbociclib was the longest among the treatment options. Further data are awaited to determine whether ET + targeted therapy with CDK4/6i and mTORi provides acceptable treatment options following ET + palbociclib.
|
Authors | Masataka Sawaki, Yasuaki Muramatsu, Kanae Togo, Hiroji Iwata |
Journal | Breast (Edinburgh, Scotland)
(Breast)
Vol. 70
Pg. 1-7
(Aug 2023)
ISSN: 1532-3080 [Electronic] Netherlands |
PMID | 37267715
(Publication Type: Observational Study, Journal Article)
|
Copyright | Copyright © 2023 The Authors. Published by Elsevier Ltd.. All rights reserved. |
Chemical References |
- palbociclib
- Pyridines
- Piperazines
- Cyclin-Dependent Kinase 4
- Protein Kinase Inhibitors
- Receptor, ErbB-2
|
Topics |
- Humans
- Female
- Breast Neoplasms
(etiology)
- Japan
- Pyridines
(therapeutic use)
- Piperazines
- Antineoplastic Combined Chemotherapy Protocols
(therapeutic use)
- Cyclin-Dependent Kinase 4
- Protein Kinase Inhibitors
(therapeutic use)
- Receptor, ErbB-2
|